A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Fatty Liver, sponsored by Sanofi. Terminated at 24 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-18.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 211 studies in Fatty Liver with a site in United States — 41 open to participants now, 47 under way, 8 of them phase 3. Fatty Liver · United States.
Among the 211 studies in Fatty Liver with a site in United States, this one is the 58th largest by enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2008, is one of 15 in phase 3, and was the 28th registered.
663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.
Browse Fatty Liver studies →41 of the 211 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Madrigal Pharmaceuticals, Inc. · Sites in United States
Ages 18+
Kriya Therapeutics, Inc. · Sites in United States, New Zealand
Ages 18–75
Altimmune, Inc. · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
211 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 57 · Phase 3 17 · Phase 4 12
First in 2001; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 60 across 432 interventional studies indexed under Fatty Liver.
Median enrollment 45 across the 162 interventional studies, 85 across the 48 observational. Of the 149 that completed or were terminated, 63 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 211 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
13 of the studies in Fatty Liver with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06354088Columbia UniversityHuman Models of Selective Insulin Resistance: Alpelisib, Part I | 2026-12-31 |
| NCT04781322National Institute on Alcohol Abuse and Alcoholism (NIAAA)Safety, Tolerability, and Bioeffects of Alirocumab in Non-treatment Seeking Heavy Drinkers | 2026-12-31 |
| NCT06944353Northwestern UniversityImproving Diagnostic Safety Through STeatosis Identification, Risk Stratification, and Referral in the ED | 2027-01 |
| NCT07491458Rivus Pharmaceuticals, Inc.A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) | 2027-02 |
| NCT07495332Duke UniversitySiemens Biomarker Multi-modality | 2027-05 |
Add all 13 to your calendar (.ics) → With an account.
Among the 211 studies in Fatty Liver with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effect of rimonabant treatment on the histological features of Nonalcoholic Steatohepatitis (NASH) in patients with Type 2 diabetes.
The total duration per patient will be approximately 22 months including a 18-month double-blind treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Rimonabant 20 mg once daily.
Drug: Rimonabant
Placebo (for Rimonabant) once daily.
Drug: Placebo (for Rimonabant)
Tablet, oral administration
Also known as: SR141716, Acomplia
Tablet, oral administration
Mean change per year in Non-Alcoholic Fatty Liver Disease [NAFLD] Activity Score (NAS)
Time frame: Baseline to 18 months
Change from baseline in hepatic fibrosis score
Time frame: Baseline to 18 months
Change from baseline in serum hyaluronate and hepatic transaminases (AST/ALT)
Time frame: Baseline to 18 months
The record gives a start of Feb 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimonabant